ACC.20/WCC

ACC.20/WCC: PRECOMBAT Trial: 10-Year Data Show Cardiac Stenting Equal to CABG in Preventing Events

People receiving a stent are more likely to need a repeat procedure to open the blocked artery

WASHINGTON (Mar 29, 2020) - In a study with the longest follow-up to date of patients with a high-risk form of heart disease known as left main coronary artery disease (LMCAD), researchers found no significant differences in rates of death, heart attack or stroke between patients who were treated with a stent and those who underwent heart bypass surgery. The research, presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC), also showed that more patients receiving a stent had to have the procedure repeated during the study period.

LMCAD is a condition in which the main coronary artery that supplies blood to the chambers on left side of the heart becomes blocked by a buildup of fatty deposits, or plaque. The left-side heart chambers push blood out to the body and are larger than the right-side chambers, which receive blood and send it to the lungs to be resupplied with oxygen. People with blockages in the arteries serving the left side of the heart are at higher risk for a heart attack or stroke than people with other forms of coronary artery disease.

Surgery is considered a more durable procedure and has been regarded as the standard of care for patients with LMCAD, according to researchers.

“Our findings support the long-term safety and efficacy of stenting compared with bypass surgery after more than 10 years of follow-up in a patient population with a poor outlook,” said Duk-Woo Park, MD, of Asan Medical Center, Seoul, South Korea, and first author of the study.

In the trial, known as PRECOMBAT, 600 patients with LMCAD were randomly assigned either to receive a drug-releasing stent or to undergo CABG at 13 medical centers in South Korea between 2004 and 2009. The average age of patients at treatment was 62.3 years, 76.5% were men and 32% were being treated for diabetes.

The primary study endpoint was the combined occurrence of death from any cause, heart attack, stroke or the need for a second procedure to unblock the same artery. The trial was designed to determine whether outcomes with stenting were not worse than with CABG. Follow-up results at one year and five years, published in 2011 and 2015, found no significant differences between the two groups for the primary endpoint or for any of its components except that patients treated with a stent were more likely to need a second procedure to unblock the same artery.

In the current study, the median length of follow-up was 11.3 years. Data showed that 87 patients treated with a stent (29.8%) and 72 treated with bypass surgery (24.7%) had died, had a heart attack or stroke, or needed a second procedure to unblock the same artery, a difference that was not statistically significant. However, when the researchers looked only at the proportion of patients who required a second procedure, the difference between the groups was statistically significant, with 16.1% of patients receiving a stent needing a second procedure compared with 8% of those who had bypass surgery.

Of note, patients enrolled in the PRECOMBAT trial were treated with “first-generation” drug-coated stents. The “second-generation” stents being used today are both safer and more effective than the ones that were available 16 years ago when the PRECOMBAT study began, Park said, adding that additional studies are needed to assess the outcomes after 10 or more years of follow-up for patients treated with these second-generation stents.

“Our extended follow-up provides important insights on long-term outcomes, which may aid in decision-making about the optimal treatment strategy for patients with LMCAD,” he said, noting that two other recently published studies comparing stenting with bypass surgery in patients with LMCAD had reached conflicting conclusions. The EXCEL trial, published in the New England Journal of Medicine in November 2019, found no significant difference in outcomes after five years of follow-up between patients who received stents and those who had bypass surgery. By contrast, the NOBLE trial, published in The Lancet in December 2019, found that bypass surgery was superior to stenting after five years of follow-up.

PRECOMBAT was funded by the Cardiovascular Research Foundation.

The findings were simultaneously published online in the journal Circulation at the time of presentation.

ACC.20/WCC will take place March 28-30, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC20/#WCCardio for the latest news from the meeting.

The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care and offers cardiovascular accreditation to hospitals and institutions. For more, visit acc.org.